Efficacy and safety of mifepristone in patients with uterine fibroids

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Objective: To evaluate the efficacy and safety of Gynestril, 50 mg tablet, in patients with symptomatic uterine fibroids in routine clinical practice.

Materials and methods: This was an open, multicenter, non-interventional, prospective study conducted on the basis of seven Russian clinical centers between 2022 and 2023 in order to investigate the therapeutic efficacy and safety of Gynestril in patients with symptomatic uterine fibroids in routine clinical practice (GYNNEO). All patients (n=234) were administered the drug orally, in the form of a single tablet, once a day on days 1-3 of the menstrual cycle for a period of three months (one course of treatment). The efficacy and safety of the treatment were evaluated during the patients’ visits to the centers: before the drug was prescribed, immediately after completing the treatment with its course for three months and three months after completing the treatment. Efficacy was assessed by changes in the volume and largest linear size of the dominant myomatous node and nodes 2 and 3, which were considered to be the second and third nodes in diameter after the dominant node (provided that their initial diameter was less than 1.5 cm), uterine volume, number of visualized nodes, endometrial thickness, resistance index (RI) and blood flow velocity in the nodes, hemoglobin level, dynamics of symptom severity according to the 5-point Likert scale, etc. The incidence and characteristics of adverse and serious events were considered in the safety assessment.

Results: According to the ultrasound data, the volume of the dominant myomatous node decreased by 33% after three months of therapy with Gynestril and by 59.5% after three months of follow-up compared to baseline (pre-treatment) level. A number of other efficacy endpoints also showed positive trends during the study. They included decreases in volume of nodes 2 and 3, uterine volume, maximum linear size of the nodes, increased RI, and decreased blood flow velocity in the nodes. The severity of the symptoms associated with the disease (pain, dyspareunia, and symptoms of compression) was found to decrease with the complete elimination of moderate and severe symptoms after three months of therapy. Half of the patients had amenorrhea after the treatment and it persisted in 101/234 (43%) patients for three months after completing the treatment with Gynestril. During the study, there were 26/226 (11%) adverse events related to treatment.

Conclusion: The study demonstrates that treatment with Gynestril results in a statistically significant decrease in the volume of myomatous nodes after three months of therapy (immediately after the course) and this effect persists for three months following the completion of the course of therapy. Therapy with Gynestril controls and reduces the severity of symptoms of the disease and the amount of menstrual blood loss. The drug is generally well tolerated by patients.

About the authors

Alexander L. Tikhomirov

Russian University of Medicine, Ministry of Health of Russia

Author for correspondence.
Email: tikhomiroval@yandex.ru

Professor, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology of the Medical Faculty

Russian Federation, 127473, Moscow, Delegatskaya str., 20/1

Mekan R. Orazov

Peoples’ Friendship University of Russia

Email: tikhomiroval@yandex.ru

Professor, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology with a course in perinatology of the Medical Institute

Russian Federation, 117198, Moscow, Miklukho-Maklaya str., 6

Oxana A. Melkozerova

Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia

Email: abolmed1@mail.ru
ORCID iD: 0000-0002-4090-0578

Dr. Med. Sci., Associate Professor, Deputy Director for Science

Russian Federation, 620028, Yekaterinburg, Repin str., 1

Antonina A. Smetnik

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_smetnik@oparina4.ru
ORCID iD: 0000-0002-0627-3902

PhD, Head of the Department of Gynecological Endocrinology, President of the Russian Society of Specialists in Gynecological Endocrinology and Menopause

Russian Federation, 117997, Moscow, Ac. Oparin str., 4

Elena I. Ermakova

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: e_ermakova@oparina4.ru
ORCID iD: 0000-0002-6629-051X

PhD, Senior Researcher at the Department of Gynecological Endocrinology

Russian Federation, 117997, Moscow, Ac. Oparin str., 4

Nadezhda Yu. Katkova

Privolzhsky Research Medical University, Ministry of Health of Russia

Email: katkova_nu@inbox.ru

Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Additional Vocational Education

Russian Federation, 603005, Nizhny Novgorod, Minin and Pozharsky sqr., 10/1

Vitaly F. Bezhenar

Pavlov First St. Petersburg State Medical University, Ministry of Health of Russia

Email: bez-vitaly@yandex.ru
ORCID iD: 0000-0002-7807-4929

Dr. Med. Sci., Professor, Head of the Department of Obstetrics, Gynecology and Neonatology/Reproductology, Head of the Clinic of Obstetrics and Gynecology

Russian Federation, 197022, St. Petersburg, Leo Tolstoy str., 6-8

Elena Yu. Antropova

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: antropoval@mail.ru
ORCID iD: 0000-0002-5991-5163

PhD, Associate Professor at the Department of Obstetrics and Gynecology, Kazan State Medical Academy, obstetrician-gynecologist, Clinic «Institute of Health and Longevity»

Russian Federation, 420012, Republic of Tatarstan, Kazan, Mushtari str., 11

Alexandr N. Rymashevsky

Rostov State Medical University, Ministry of Health of Russia

Email: rymashevskyan@mail.ru
ORCID iD: 0000-0003-3349-6914

Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology No. 1

Russian Federation, 344022, Rostov-on-Don, Nakhichevan Lane, 29

Anna A. Mikhelson

Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia

Email: ann_tolmik@mail.ru
ORCID iD: 0000-0003-1709-6187

Dr. Med. Sci., Associate Professor, Head of the Department of Reproductive Functions Preservation

Russian Federation, 620028, Yekaterinburg, Repin str., 1

Ekaterina S. Baranova

Privolzhsky Research Medical University, Ministry of Health of Russia

Email: ekaterinabaranova94@mail.ru

Teaching Assistant, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Faculty of Additional Vocational Education

Russian Federation, 603005, Nizhny Novgorod, Minin and Pozharsky sqr., 10/1

Anna E. Grigorian

Pavlov First St. Petersburg State Medical University, Ministry of Health of Russia

Email: annagrigoryan2112@mail.ru
ORCID iD: 0000-0002-1674-7753

PhD Student at the Department of Obstetrics, Gynecology and Neonatology

Russian Federation, 197022, St. Petersburg, Leo Tolstoy str., 6-8

References

  1. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Миома матки. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Uterine fibroids. 2024. (in Russian)].
  2. Беженарь В.Ф., Линде В.А. Миома матки и аденомиоз. Стратегия органосбережения. СПб.: Медконгресс; 2023. 136 с. [Bezhenar V.F., Linde V.A., eds. Uterine myoma and adenomyosis. Organ saving strategy. St. Petersburg: Medkongress; 2023. 136 p. (in Russian)].
  3. Bartels C.B., Cayton K.C., Chuong F.S., Holthouser K., Arian S.E., Abraham T. et al. An evidence-based approach to the medical management of fibroids: a systematic review. Clin. Obstet. Gynecol. 2016; 59(1): 30-52. https://dx.doi.org/10.1097/GRF.0000000000000171.
  4. Беженарь В.Ф., Линде В.А., Аракелян Б.В., Садыхова Э.Э., Резник М.В., Тарасенкова В.А. Миома матки и фертильность: современный взгляд на проблему (обзор литературы). Журнал акушерства и женских болезней. 2022; 71(2): 79-86. [Bezhenar V.F., Linde VA, Arakelyan B.V., Sadykhova E.E., Reznik M.V., Tarasenkova V.A. Uterine fibroids and fertility: a modern view of the problem. A literature review. Journal of Obstetrics and Women's Diseases. 2022; 71(2):79-86. (in Russian)]. https://dx.doi.org/10.17816/JOWD78831.
  5. Беженарь В.Ф., Павлова Н.Г., Цыпурдеева А.А., Прохорова В.С., Медведева Н.С. Неоадъювантная терапия гинестрилом при органосохраняющих операциях на матке. Журнал акушерства и женских болезней. 2007; LVII (Спецвыпуск): 92-4. [Bezhenar V.F., Pavlova N.G., Tsypurdeeva A.A., Prokhorova V.S., Medvedeva N.S. Neoadjuvant therapy with ginestril in organ-preserving operations on the uterus. Journal of Obstetrics and Women's Diseases. 2007; LVII (Special issue): 92-4 (in Russian)].
  6. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., Yen S.S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab. 1993; 76(2): 513-7. https://dx.doi.org/10.1210/jcem.76.2.8432797.
  7. Kulshrestha V., Kriplani A., Agarwal N., Sareen N., Garg P., Hari S. et al. Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from North India. Indian J. Med. Res. 2013; 137(6): 1154-62.
  8. Bagaria M., Suneja A., Vaid N.B., Guleria K., Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust. N. Z. J. Obstet. Gynaecol. 2009; 49(1): 77-83. https://dx.doi.org/10.1111/j.1479-828X.2008.00931.x.
  9. Esteve J.L., Acosta R., Pérez Y., Rodriguez B., Seigler I., Sanchez C. et al. Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int. J. Womens Health. 2013; 5: 361-9. https://dx.doi.org/10.2147/IJWH.S42770.
  10. Esteve J.L., Acosta R., Pérez Y., Campos R., Hernández A.V., Texidó C.S. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomized clinical trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 161(2): 202-8. https://dx.doi.org/10.1016/j.ejogrb.2011.12.018.
  11. Jain D. Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome. J. Midlife Health 2018; 9(2): 65-71. https://dx.doi.org/10.4103/jmh.JMH_100_17.
  12. Engman M., Granberg S., Williams A.R., Meng C.X., Lalitkumar P.G., Gemzell D.K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009; 24(8): 1870-9. https://dx.doi.org/10.1093/humrep/dep100.
  13. Seth S., Goel N., Singh E., Mathur A.S., Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J. Midlife Health. 2013; 4(1): 22-6. https://dx.doi.org/10.4103/0976-7800.109630.
  14. Gupta M., Jamwal N., Sabharwal S., Sobti S. A prospective interventional study to evaluate the effects of medical therapy (Mifepristone 25 mg) on the management of uterine fibroids. J. Family Med. Prim. Care. 2020; 9(7): 3230-5. https://dx.doi.org/10.4103/jfmpc.jfmpc_467_20.
  15. Mukherjee S., Chakraborty S. A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri. Niger Med. J. 2011; 52(3): 150-2. https://dx.doi.org/10.4103/0300-1652.86123.
  16. Shen Q., Hua Y., Jiang W., Zhang W., Chen M., Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil. Steril. 2013; 100(6): 1722-6.e1-10. https://dx.doi.org/10.1016/j.fertnstert.2013.08.039.
  17. Tristan M., Orozco L.J., Steed A., Ramírez-Morera A., Stone P. Mifepristone for uterine fibroids. Cochrane Database Syst. Rev. 2012; 2012(8): CD007687. https://dx.doi.org/10.1002/14651858.CD007687.pub2.
  18. Arora D., Chawla J., Kochar S.P.S., Sharma J.C. A randomized control trial to assess efficacy of Mifepristone in medical management of uterine fibroid. Med. J. Armed Forces India. 2017; 73(3): 267-73. https://dx.doi.org/10.1016/j.mjafi.2017.02.013.
  19. Seth S., Goel N., Singh E., Mathur A.S., Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J. Midlife Health. 2013; 4(1): 22-6. https://dx.doi.org/10.4103/0976-7800.109630.
  20. Liu C., Lu Q., Qu H., Geng L., Bian M., Huang M. et al. Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial. Medicine (Baltimore) 2017; 96(7): e6124. https://dx.doi.org/10.1097/md.0000000000006124.
  21. Sruhya M., Hari A. A prospective and interventional study of the role of low dose mifepristone in the management of uterine leiomyoma in perimenopausal women. Saudi J. Med. Pharm. Sci 2017; 3: 1088-96. https://dx.doi.org/10.4103/jfmpc.jfmpc_467_20.
  22. Alakananda, Basumatary B., Sreeja Reddy B. Mifepristone in the medical management of uterine fibroids. Indian Journal of Applied Research. 2019; 9(1). https://dx.doi.org/10/36106/ijar.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».